Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AS03-adjuvanted H5N1 pandemic influenza vaccine formulations in children aged 3 to 9 years
2006-001168-22Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Influenza A H5N1 infection (H5N1) comparing AS03-adjuvanted H5N1 vaccine formulation arm with Fluarix control arm (2 arms). Primary endpoints: Humoral immune response by anti-haemagglutinin antibody titer, Humoral immune response by neutralizing antibody titer and 1 more. Started Nov 2006; status: completed.
02
Drugs
H5N1 vaccine + AS03Fluarix
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on 2006-001168-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001168-22.